Eleusis is a company developing the therapeutic potential of serotonin 2A receptor agonists, also known as psychedelics, through the mitigation and management of psychoactivity. The company builds a platform of drug discovery and digital health technologies enabling the advance of therapeutics targeting needs across inflammatory and stress-related diseases.